
Enlight Renewable Energy signs agreement for up to 150 MW data centre
The partners will split development expenses and bank guarantees estimated at NIS334 million, with grid approval still required.

Cash stood at US$0.71 million at quarter-end as cobalt deliveries moved into early 2027 and a proposed asset sale remained conditional.

The partners will split development expenses and bank guarantees estimated at NIS334 million, with grid approval still required.

The maiden drilling tested mineralisation to about 75 metres vertically, with a drone survey due by late November to guide deeper holes.
The Alberta Growth Connector needs commercial support and approvals; TC Energy disclosed no budget or specific in-service date.
The company reports US$10 million raised through its SATS preferred-share program, with no updated common-share count in the CEO's post.

Private consumption fell 0.3 per cent in July-September, while net exports subtracted 0.6 percentage points from quarterly growth.

Florida regulators counted 170 Trulieve locations on Nov. 6; the new store announcement gives no updated statewide total or first sales date.

FTSE Russell's next list update is Nov. 20, with membership changes scheduled to take effect after the Dec. 11 market close.

The proposed purchase adds carotid and clot-removal devices, with possible later payments and closing expected in Medtronic's fiscal third quarter.
Common-share sales and interest income funded the preferred buyback, while the December dividend rate stays at 12 per cent.
The nickel project's buyer would assume rehabilitation obligations, while IGO retains lithium rights and receives performance rights.
Follow-up drilling will test a south-plunging shoot in fresh rock and additional targets along the 1.5-kilometre Celia South corridor.
The tally includes buildings, power systems and planned investment, while NVIDIA's revenue outlook excludes China data centre compute sales.
The company held C$2.356 million in cash at Sept. 30 and is negotiating a non-binding proposal to acquire a controlling stake in a Polish drone business.
Trading continues on Nasdaq and the TSX as the cannabis producer faces a consecutive-day bid-price test to regain compliance.
The Ghana producer faces a Nov. 30 deadline to secure at least US$100 million in new funding and plans a January turnaround update.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
The explorer omitted ownership stakes, acquisition price and placement terms, with technical reporting targeted for year-end.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
The kidney-drug developer expects its cash and securities to last beyond 2027, including spending for a potential OLC launch.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The listed property vehicle plans a 75.1 per cent interest in two campuses, with a 7 per cent initial capitalization rate.
The Swedish company reports 3,506 bitcoin and zero-interest convertible debt, but discloses no new credit commitment or collateral terms.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
The Financial Times identifies Amazon as the customer, while Fermi says a definitive long-term lease remains under negotiation.

The explorer will reassess working capital needs and financing alternatives after dropping its October offering.

The Grand Est site will recover cobalt, nickel and copper from black mass, but Veolia disclosed no investment cost or earnings forecast.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
International medical sales supplied 59 per cent of quarterly revenue, while gross margin and adjusted EBITDA declined sequentially.

Canada and Germany have completed competition reviews, Curaleaf says, while its offer remains outstanding until Dec. 4.

The board accepted its committee's recommendation on Oct. 26, citing the harvest, a stronger outlook and debt repayment.

The submission draws on studies involving more than 1,000 participants, with a first-half 2027 launch still subject to FDA approval.